Triple-Positive and Already Failed Once: Does This Pregnancy Get More Anticoagulation Than the Guideline Says
Standard-dose aspirin and prophylactic heparin already failed her once, in a pregnancy that ended in the second trimester — and the guideline she's being treated under wasn't built for someone who's already proven it isn't enough.
A.C., a 33-year-old architect, is eight weeks into a pregnancy she and her husband began trying for again only after a year of grief following a loss at 16 weeks last year — a loss that happened despite being on low-dose aspirin and prophylactic-dose enoxaparin for confirmed triple-positive antiphospholipid syndrome, diagnosed after a prior first-trimester loss the year before that. Triple positivity — lupus anticoagulant, anticardiolipin antibody, and anti-beta2-glycoprotein I antibody all present together — identifies the highest-risk phenotype within antiphospholipid syndrome, the profile Pengo and colleagues characterized as carrying meaningfully higher rates of both thrombosis and pregnancy morbidity than single- or double-antibody positivity, though most of the randomized evidence behind standard obstetric APS treatment predates routine antibody-profile stratification this granular.
She has never had a venous or arterial thrombotic event outside of pregnancy, which is the detail that keeps her, by strict criteria, in the purely obstetric APS category rather than the combined thrombotic-and-obstetric category guidelines already treat with therapeutic-dose anticoagulation. The EULAR recommendations for antiphospholipid syndrome in adults call for exactly the aspirin-and-prophylactic-LMWH regimen that already failed her — a regimen that has functioned, in her case, as a real-world negative result rather than a hypothetical concern about undertreatment. She has told her hematologist plainly that she does not want to try the same plan a second time and watch for the same outcome, and asked directly whether the observational data on triple-positive patients supports doing something different this time.
Her first loss, in the initial trimester the year before, was originally attributed to a chance chromosomal abnormality before the antiphospholipid workup was even sent — a detail that, in retrospect, likely delayed her diagnosis and meant she entered last year's pregnancy already a full cycle behind where earlier testing might have placed her, a fact she has mentioned to her hematologist more than once since the second loss.
She and her husband are both aware, without needing it stated aloud, that they are not young by the standard obstetric calendar, and that another loss would mean starting again later than either of them had originally planned — a pressure that sits underneath tonight's conversation even though nobody at the table has treated it as a reason to override what the evidence can and can't support.
At 8 weeks, deciding before this pregnancy repeats the last one
She's already given us the answer to whether standard therapy works for her — it doesn't. Triple positivity is the documented highest-risk antibody profile in this syndrome, and I don't think we should wait for a second real-world failure to treat that as meaningful evidence. I'd escalate to therapeutic-dose enoxaparin now, at the start of this pregnancy, not after another loss.
I understand the instinct, but the evidence behind therapeutic-dose anticoagulation in purely obstetric APS — no thrombotic history outside pregnancy, which is her situation — is observational and registry-based, not from randomized trials. A full pregnancy on therapeutic-dose LMWH carries real bleeding risk and meaningful heparin-induced bone loss risk. I'm not comfortable calling one prior loss on standard therapy proof that maximal escalation is the right next step.
One failure is real information, but it's an n of one, and the guideline wasn't wrong on the day it was written just because it didn't work for her specifically.
I'd name an option neither of you has put on the table yet: this doesn't have to be a binary choice between repeating exactly what failed and going all the way to therapeutic-dose anticoagulation. Adding hydroxychloroquine has real, if also observational, support specifically in refractory obstetric APS, and intensified prophylactic-dose LMWH is a genuine intermediate step. I'd start there rather than jump to either end of the spectrum on the strength of one prior loss.
This isn't a resolution either of you will fully agree with tonight, and I don't think it should be — her case sits in real, acknowledged evidence uncertainty, and she deserves to know that directly rather than have it presented as settled.
Not agreed, and stated to her honestly as such: the team could not reach consensus on therapeutic-dose anticoagulation tonight. What was agreed — aspirin continued, hydroxychloroquine added, prophylactic-dose enoxaparin intensified to the higher end of its dosing range, with maternal-fetal medicine following her closely and an explicit, low threshold to revisit therapeutic-dose anticoagulation at the first sign of placental insufficiency on ultrasound.
She was told directly that this reflects genuine, acknowledged uncertainty in the evidence for her specific antibody profile and history, not a confident answer being withheld from her.